By Kamal Choudhury and Christy Santhosh April 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly ...

This drug has boxed warnings. These are the most serious warnings from the Food and Drug Administration (FDA). A boxed warning alerts doctors and patients about drug effects that may be dangerous.

AbbVie reported that its JAK inhibitor Rinvoq showed superior efficacy to its TNF inhibitor Humira in rheumatoid arthritis patients who had not responded to prior TNF therapy. The phase 3b/4 ...

The FDA recently designated Yuflyma as "interchangeable" with the popular biologic Humira for the treatment of Crohn's disease and ulcerative colitis, two types of inflammatory bowel disease (IBD), ...

NEW YORK, May 21 (Reuters) - Abbott Laboratories Inc said on Wednesday its Humira medicine has maintained maximum effectiveness for a year or longer among roughly 29 percent of Crohn's disease ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...

As with other medications, Humira can interact with certain other drugs. It can also interact with some vaccines. An interaction occurs when one substance causes another substance to have a different ...

Humira (adalimumab) is a long-term maintenance medication used to manage chronic conditions like Crohn’s disease and rheumatoid arthritis. For many people, this drug is not a short-term fix but a ...

AbbVie (NYSE:ABBV) has attracted persistent buying interest, and every pullback has drawn in value-focused investors. The ...

Switching to CT-P17 resulted in stable or increased patient satisfaction, especially for those previously on biosimilars or citrate-containing formulations. Patient education and shared ...

(Reuters) - AbbVie Inc, which last week announced plans to buy Dublin-based drugmaker Shire Plc for $55 billion, reported stronger-than-expected quarterly earnings on surging sales of its Humira ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Beginning in 2023, five years after their European counterparts, ...